Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Pembrolizumab in RCC with Brain Metastasis
NCT07011849Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jun 2025; status: withdrawn.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07011849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011849.